Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Novo Nordisk has reported results from a 26-week randomized multinational Phase IIIb trial, which showed that Ryzodeg (insulin degludec/insulin aspart) administered twice daily, provides successful glycaemic control with fewer injections than a basal-bolus regimen.
Subscribe to our email newsletter
The company said that the trial failed to meet its primary endpoint of non-inferiority; however, the results showed that HbA1c was reduced for patients on either regimen, to 7.0% and 6.8% respectively, with no significant difference between the two regimens.
Ryzodeg is a combination of two distinct insulin analogues including insulin degludec and insulin aspart in the ratio of 70% and 30%.
In the trial, patients previously treated with basal insulin were randomized to a regimen of either twice daily Ryzodeg, or a basal-bolus regimen of once-daily insulin degludec plus two to four injections of insulin aspart.
Study principal investigator and endocrinologist in Rockville Helena Rodbard said patients currently using basal-bolus regimens may need to take up to four daily injections, which can be a great burden and very inconvenient.
"Ryzodeg is a new treatment option which provides proven glycaemic control, with fewer injections and reduced rates of hypoglycaemia compared to basal-bolus regimens," Rodbard said.
"This new treatment offers the potential for a simple alternative to basal-bolus for patients who require intensification of basal insulin regimens."